Researchers from La Jolla Institute for Immunology have found that human T cells can target more than 1,400 sites on the SARS-CoV-2 virus, revealing a broad and diverse immune response. This analysis can help monitor effective responses to COVID-19 vaccines and track variations in T cell responses.
A new study reveals how Ebola virus's VP40 protein uses human mRNA to transform into different shapes, adapting to various functions. This discovery sheds light on the fundamentals of genome-encoded information and highlights VP40 as a key vulnerability for effective therapies.
Researchers have identified a key protein, DAPK3, that plays a crucial role in the body's early immune response to cancer. The discovery highlights a new approach to cancer immunotherapy, where targeting the tumor's own innate immune system can help slow tumor growth and improve treatment outcomes.
A phase 2 trial led by La Jolla Institute for Immunology (LJI) shows a promising combination therapeutic candidate for adults with recent-onset type 1 diabetes. The treatment combines anti-IL-21 antibody with liraglutide and has been found to increase endogenous insulin secretion without safety concerns.
A recent study published in Cell Report Medicine has provided a detailed look at the vulnerable sites on the novel coronavirus SARS-CoV-2 that T cells can attack. The research found that T cells can recognize dozens of epitopes on the virus, including several additional sites on the spike protein.
A new study reveals that people with severe COVID-19 cases have stronger long-term immunity due to a higher number of protective memory T cells. In contrast, those with milder cases may experience T cell exhaustion, which can hinder their ability to build long-term immunity.
A new study found that COVID-19 survivors have immune cells necessary to fight re-infection, with virus-specific antibodies and memory B cells persisting in the bloodstream. This suggests that people may have protective immunity against serious disease for at least eight months after infection.
Researchers at La Jolla Institute for Immunology created 3D maps of how enhancer sequences and genes interact in several types of immune cells. The new study opens the door to understanding individual risk for diseases from asthma to cancer.
Scientists at La Jolla Institute for Immunology have found elongated neutrophil-derived structures (ENDS) in the blood of septic patients, which break off from immune cells and change shape as they course through the body. ENDS are 100-fold more detectable in sepsis patients than healthy individuals.
Researchers at La Jolla Institute for Immunology have discovered that blocking OX40L and CD30L, two key immune molecules, is crucial to preventing asthma attacks. The study shows how these molecules contribute to inflammation in the lungs during an allergic reaction.
A new study suggests that combining T cell activation with antibody production could lead to longer-term protection against Zika virus. Researchers found that inducing CD8+ T cells was key in preventing Zika infection in mice, offering a promising approach for developing effective vaccines.
Researchers at La Jolla Institute for Immunology discovered that even healthy individuals have high numbers of preproinsulin-specific T cells in their pancreas. These cells are believed to be the prime suspects in triggering the autoimmune response that causes type 1 diabetes.
A new study provides an in-depth look at how CD4+ T cells respond to SARS-CoV-2, revealing a novel T cell subset that may contribute to severe COVID-19 cases. The research also found that dysfunctional TFH cells can lead to reduced antibody production and worsen disease severity.
Researchers at La Jolla Institute for Immunology report that protein TL1A drives fibrosis in several mouse models, triggering tissue remodeling and making it harder for lungs and airways to function normally. This discovery suggests potential targets for therapeutics aimed at reducing fibrosis and tissue remodeling.
Researchers found that a strong, coordinated T cell response is predictive of milder disease, while poor immune coordination leads to severe outcomes. Older adults' susceptibility to COVID-19 may be linked to declining naïve T cells and weaker adaptive immune responses.
Scientists at La Jolla Institute for Immunology discover that high-valency antigens can lead to a more-is-better immune system reaction, while low-valency antigens result in a smaller, more targeted B cell response. The study suggests that selecting antigens with the right valency will depend on the disease being targeted.
A new study from La Jolla Institute for Immunology found that blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes. The researchers used a mouse model and discovered that blocking sympathetic nerve signals protected mice from beta cell death.
Scientists at La Jolla Institute for Immunology have tracked down the rare stem cells that generate neutrophils in human bone marrow, offering a potential path for intervening in diseases where neutrophil development goes awry. This research may also provide clues to COVID-19 and cancer drug targets.
A new study suggests that exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2, potentially leading to milder or more severe COVID-19 symptoms. The research found that memory helper T cells recognizing common cold coronaviruses also recognized matching sites on SARS-CoV-2.
A new study reveals that certain T lymphocytes can increase inflammation and worsen atherosclerosis cases, contrary to their usual role as immune system defenders. Researchers at La Jolla Institute for Immunology are working to design a safe anti-atherosclerosis vaccine by harnessing the power of T cells.
A new study from La Jolla Institute for Immunology reveals that a metabolic enzyme called ADA2 inhibits inflammation in blood vessels and restrains the immune system. The researchers found that ADA2's loss stimulates a robust innate immune response, which can lead to harmful inflammation.
A small variation in the novel coronavirus has made it fitter, resulting in a higher viral load, but does not make it more deadly. The G version of the virus dominates cases worldwide, suggesting it may be more transmissible.
A new study found that T cells targeting the SARS-CoV-2 virus can help fight COVID-19, even in severe cases. The research also reveals similar responses to the virus among Dutch and American patients.
Researchers at La Jolla Institute for Immunology have identified a key protein controlling T follicular helper cell (Tfh) differentiation. The protein Bcl6 acts as a master regulator in the immune system, blocking or promoting gene expression to control immune responses. This study opens the door to designing vaccines and therapies tha...
Researchers at La Jolla Institute for Immunology have uncovered a previously unknown subset of T cells that may control allergic immune reactions and asthma. These cells, which express an 'interferon response signature,' may dampen the activation of helper T cells and reduce inflammation.
Researchers at La Jolla Institute for Immunology discovered that antibodies against one virus can make another more severe. However, a specific type of T cell can counteract this effect. The study suggests the need for future vaccines to elicit a balanced response from both antibodies and T cells.
Scientists have discovered a strong immune response to SARS-CoV-2 in people who have recovered from COVID-19, which provides a benchmark for testing vaccine candidates. The study also found substantial cross-reactivity against common cold coronaviruses, suggesting potential preexisting immunity.
Researchers found signs of autoimmunity in Parkinson's patients years before diagnosis, providing potential for early detection and treatment. The study also showed that immune responses change over time, with more aggressive cells initially causing damage.
The Coronavirus Immunotherapy Consortium will streamline and accelerate the development of antibody therapies against SARS-CoV-2, providing crucial insights to guide vaccine development. CoVIC brings together scientists worldwide to share and evaluate candidate antibodies in a blinded analysis.
Researchers used existing data from known coronaviruses to predict which parts of SARS-CoV-2 are capable of activating the human immune system. The study identified five regions in the spike glycoprotein, membrane protein, and nucleoprotein that elicit a strong immune response.
Scientists at La Jolla Institute for Immunology found no evidence linking CD4 T cells to severe dengue hemorrhagic fever. Instead, they discovered a novel T cell response that may help counteract inflammation, suggesting a new direction for developing effective vaccines.
Researchers from the La Jolla Institute for Immunology identified a new role for HMCES in alternative end-joining, a secondary strategy used by mammalian cells to rejoin severe cuts across both strands of DNA. This discovery suggests that HMCES is versatile enough to accomplish entirely different tasks in response to DNA damage.
La Jolla Institute of Immunology and Seqster partner to accelerate discovery of personalized treatments for severe asthma through longitudinal data analysis. The collaboration enables 5000 participants to share medical records, genomic data, and wearable device data with researchers.
Researchers at La Jolla Institute for Immunology identified the molecular properties of antibodies that neutralize Lassa virus. By understanding these properties, they can create a map for rational vaccine design, aiming to develop effective treatments or vaccines against this deadly disease.
Researchers reveal how TET proteins convert 5mC to 5hmC, preventing genomic instability and cancer. Defects in TET function are linked to increased levels of DNA damage and genome instability, highlighting the importance of maintaining a balance between DNA methylation and demethylation.
A study published in eLife found that doublet immune cells are more common than previously thought and play a crucial role in disease progression. The research reveals that these cell complexes can serve as biomarkers for immune perturbations, potentially allowing for early detection of diseases like dengue fever.
Researchers found that eliminating key gene regulatory factors, such as NR4A and TOX, fortifies T cell attack on melanoma cells, leading to improved tumor rejection and survival. This discovery suggests a potential strategy for extending CAR T-based immunotherapy to solid tumors.
Scientists at La Jolla Institute for Immunology developed a new HIV vaccine delivery strategy that enhances the protective immune response by slowly releasing vaccine doses. This approach, called escalating dose strategy, leads to stronger and more neutralizing antibodies against the virus.
Researchers at the La Jolla Institute for Immunology discovered that genetic deletion of TET2 and TET3 in mouse B cells impairs the generation of functional IgG antibodies, highlighting the critical role of epigenetic control in healthy immune cell function.
Researchers at the La Jolla Institute of Immunology have identified Nr4a transcription factors as a key regulator of T cell exhaustion in solid tumors. By deleting these proteins from CAR T cells, mice with tumors showed improved survival and tumor regression, offering new hope for effective cancer immunotherapies.
A study by La Jolla Institute for Immunology finds that recurrent group A strep tonsillitis is caused by a combination of genetic and immunological factors, including an insufficient antibody response against SpeA. This understanding may lead to the development of a vaccine to protect against strep throat.
The La Jolla Institute has been awarded a seven-year NIH contract renewal to host and expand the Immune Epitope Database, containing over 530,000 epitopes from 3,600 species. This vast amount of data allows researchers to unlock clues to disease causes by searching for commonalities among different pathogens.
Scientists at La Jolla Institute for Immunology have created an immune cell atlas, DICE, to decipher how natural genetic variation shapes the immune system's ability to protect health. The database provides detailed profiles of 15 immune cell types and 91 healthy donors, revealing a wide impact of genetic variation on gene activity.
A new study found that maternal Zika immunity can increase the severity of dengue disease in mouse pups, which has significant implications for vaccine development. The study suggests that a pan-flavivirus vaccine could be an effective way to elicit maximal protection against both diseases.
Researchers found that a protein pair, STIM1 and ORAI, control cellular calcium signals through structural changes. The discovery lays groundwork for novel treatments to manipulate aberrant calcium signaling in the immune system.
Researchers at La Jolla Institute and UC San Diego will develop new immunotherapeutic options and novel precision approaches to treat head and neck cancer using neoantigen-specific T cell responses. The $4.5 million Cancer Moonshot award aims to improve outcomes for patients with this devastatingly deadly disease.
A team of researchers at La Jolla Institute for Immunology has identified a previously unknown progenitor population with neutrophil characteristics, which promotes tumor growth. The discovery could serve as an early warning sign for cancer and drive new therapeutic approaches for treating neutropenia, chronic inflammation, and cancer.
A recent study published in Nature Communications found that dengue immunity provides cross-protection against Zika virus in mouse models. The research shows that cytotoxic T cells mobilized by dengue infection can combat the devastating effects of Zika infection on fetal brain development.
Researchers at La Jolla Institute found that the current whooping cough vaccine primes the immune system in a way that leaves it vulnerable to future infections. The study suggests that new vaccines could be developed to improve the vaccine's efficacy, potentially applicable to other vaccines.
Researchers at La Jolla Institute for Immunology develop a peptide vaccine that induces protective T cells and decreases plaque size in atherosclerotic mice. The vaccine targets the 'bad cholesterol' protein and expands a class of protective T cells, curbing inflammation.